Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nicotinamide-adenine-dinucleotide-5-hydroxy-4-oxonorvaline is an experimental small molecule that belongs to the class of (5'->5') dinucleotides. It is a synthetic analog of nicotinamide adenine dinucleotide (NAD) in which the molecule 5-hydroxy-4-oxonorvaline (HON) forms a covalent adduct with NAD at the C4 position of the nicotinamide ring and C5 of HON. This compound has been studied primarily for its antifungal properties, where it acts as a potent inhibitor of homoserine dehydrogenase by forming this enzyme-dependent covalent adduct, leading to antifungal activity despite weak steady-state inhibition. There are no approved indications or clinical trials for this compound; it remains an experimental agent used in biochemical and structural studies[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nicotinamide-adenine-dinucleotide-5-hydroxy-4-oxonorvaline.